Lushang Freda PharmaceuticalLtd Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Lushang Freda PharmaceuticalLtd kazanç ve gelirin sırasıyla yıllık 27.4% ve 14.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 26.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 9.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

27.4%

Kazanç büyüme oranı

26.7%

EPS büyüme oranı

Real Estate kazanç büyümesi	38.1%
Gelir büyüme oranı	14.1%
Gelecekteki özkaynak getirisi	9.1%
Analist kapsamı	Good
Son güncelleme	08 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares

Jun 21

Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Apr 16

Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Mar 28

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 04

A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Feb 27

Kazanç ve Gelir Büyüme Tahminleri

SHSE:600223 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	5,475	461	51	772	8
12/31/2025	4,852	380	3	574	9
12/31/2024	4,221	297	2,481	2,372	9
9/30/2024	3,986	237	57	208	N/A
6/30/2024	4,031	240	242	370	N/A
3/31/2024	4,197	233	213	418	N/A
12/31/2023	4,579	303	263	474	N/A
9/30/2023	7,817	130	-127	98	N/A
6/30/2023	10,590	47	84	350	N/A
3/31/2023	12,741	108	1,263	1,442	N/A
12/31/2022	12,951	45	832	998	N/A
9/30/2022	14,543	13	3,070	3,273	N/A
6/30/2022	13,131	240	4,103	4,293	N/A
3/31/2022	12,140	342	5,970	6,250	N/A
12/31/2021	12,363	362	6,567	6,848	N/A
9/30/2021	12,929	729	7,473	7,700	N/A
6/30/2021	14,137	710	7,719	7,944	N/A
3/31/2021	13,915	662	5,543	5,712	N/A
12/31/2020	13,615	639	4,291	4,448	N/A
9/30/2020	10,316	572	4,680	4,841	N/A
6/30/2020	9,817	482	39	174	N/A
3/31/2020	10,307	364	-4,831	-4,759	N/A
12/31/2019	10,289	345	-3,367	-3,307	N/A
9/30/2019	10,373	222	-5,546	-5,516	N/A
6/30/2019	10,159	195	-2,295	-2,262	N/A
3/31/2019	9,261	184	3,184	3,222	N/A
12/31/2018	8,821	162	2,062	2,095	N/A
9/30/2018	10,105	166	1,120	1,207	N/A
6/30/2018	8,694	159	N/A	1,571	N/A
3/31/2018	8,476	129	N/A	360	N/A
12/31/2017	8,287	128	N/A	1,637	N/A
9/30/2017	7,576	102	N/A	3,215	N/A
6/30/2017	7,909	98	N/A	-1,495	N/A
3/31/2017	7,370	94	N/A	-1,127	N/A
12/31/2016	7,646	92	N/A	-2,468	N/A
9/30/2016	7,151	107	N/A	-4,768	N/A
6/30/2016	5,870	101	N/A	-1,056	N/A
3/31/2016	6,118	103	N/A	-1,723	N/A
12/31/2015	5,864	112	N/A	-1,798	N/A
9/30/2015	5,109	166	N/A	-991	N/A
6/30/2015	6,365	205	N/A	-1,002	N/A
3/31/2015	5,908	207	N/A	-1,042	N/A
12/31/2014	5,682	206	N/A	-2,363	N/A
9/30/2014	6,387	287	N/A	-2,457	N/A
6/30/2014	5,790	273	N/A	-2,511	N/A
3/31/2014	5,477	272	N/A	-2,356	N/A
12/31/2013	5,293	263	N/A	-1,088	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 600223 'nin tahmini kazanç büyümesi (yıllık 27.4% ) tasarruf oranının ( 2.8% ) üzerindedir.

Kazançlar ve Piyasa: 600223 şirketinin kazançlarının (yıllık 27.4% ) CN pazarından (yıllık 26.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 600223 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 600223 şirketinin gelirinin (yıllık 14.1% ) CN pazarından (yıllık 13.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 600223 şirketinin gelirinin (yıllık 14.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 600223 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 9.1 %).

Lushang Freda PharmaceuticalLtd Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 12% to CN¥10.32

Price target increased by 8.1% to CN¥13.52

Price target increased by 7.3% to CN¥13.42

Price target increased by 8.3% to CN¥13.29

Price target decreased to CN¥11.17

Price target decreased to CN¥12.27

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.041 (vs CN¥0.043 in 3Q 2023)

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 16%

Price target decreased by 12% to CN¥10.32

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.061 in 2Q 2023)

Lushang Freda Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Doing What It Can To Lift Shares

Lushang Freda Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 25, 2024

First quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.13 in 1Q 2023)

Is Now An Opportune Moment To Examine Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)?

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Lushang Freda PharmaceuticalLtd's (SHSE:600223) Solid Earnings May Rest On Weak Foundations

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Lushang Life Services Co., Ltd. (SEHK:2376) agreed to acquire Shandong Lujian Property Management Limited from Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223) for RMB 4.9 million.

A Look At The Fair Value Of Lushang Freda Pharmaceutical Co.,Ltd. (SHSE:600223)

Investor sentiment deteriorates as stock falls 16%

Lushang Freda Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

New major risk - Financial position

Lushang Freda Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023

New major risk - Dividend sustainability

Lushang Freda Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 26, 2023

Price target increased by 8.1% to CN¥13.52

Price target increased by 7.3% to CN¥13.42

Price target increased by 8.3% to CN¥13.29

Price target decreased to CN¥11.17

Lushang Health Plans to Sell Real Estate Assets to Controlling Shareholder or Affiliates

Price target decreased to CN¥12.27

Third quarter 2022 earnings released: CN¥0.033 loss per share (vs CN¥0.19 profit in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.23 in 2Q 2021)

Price target decreased to CN¥12.87

First quarter 2022 earnings: EPS and revenues miss analyst expectations

No independent directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to CN¥16.16

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.17 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.18 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥16.10

First quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.06 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.64 (vs CN¥0.34 in FY 2019)

Lushang Health Industry Development Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 27, 2021

Investor sentiment improved over the past week

New 90-day high: CN¥14.15

New 90-day high: CN¥12.58

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥9.21

Market bids up stock over the past week

Third quarter earnings released

Lushang Health Industry Development Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥9.66

Earnings released

New 90-day high - CN¥15.60

Lushang Health Industry Development Co.,Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin